Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer

This study is testing a combination of two immunotherapy drugs (botensilimab and balstilimab) together with a fasting-mimicking diet and vitamin C in people with metastatic colorectal cancer that carries a specific mutation (any KRAS mutation) and is of the microsatellite stable (MSS) subtype — a cancer type that typically doesn't respond well to immunotherapy alone. **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of MSS metastatic colorectal adenocarcinoma with a KRAS mutation - Your cancer has progressed on or you cannot tolerate standard chemotherapy regimens (fluoropyrimidine, oxaliplatin, and irinotecan) - You have a good performance status (ECOG 0–1), a life expectancy of at least 3 months, and a BMI of 18.5 or above - Your blood counts and organ function are within acceptable ranges **You may NOT be eligible if...** - You have had prior treatment with either of the study immunotherapy drugs - You have active autoimmune disease or have received high-dose steroids recently - You have significant heart, liver, or kidney dysfunction - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.